Evidence map›Paper›PMID 17397888›Full record

ReviewToxicology and applied pharmacology2007

Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies.

Janine D Miller, Elma D Baron, Heather Scull, Andrew Hsia, Jeffrey C Berlin, Thomas McCormick, Valdir Colussi, Malcolm E Kenney, Kevin D Cooper, Nancy L Oleinick

Open access · greenAbstract readReview
In one paragraph

Review in Toxicology and applied pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it, 234 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Photodynamic Therapy: Past, Current, and Future.International journal of molecular sciences · 2024
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Janine D MillerDepartment of Dermatology, Case Western Reserve University/University Hospitals of Cleveland, Cleveland, OH 44106, USA.
Elma D Baron
Heather Scull
Andrew Hsia
Jeffrey C Berlin
Thomas McCormick
Valdir Colussi
Malcolm E Kenney
Kevin D Cooper
Nancy L Oleinick
Case Western Reserve University · USUniversity Hospitals of Cleveland · US

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
Vitamin D endocrine system and Protection Against Skin TumorlgenesisP30AR039750 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · PI COOPER, KEVIN D · 1988 to 2015
$9.1M
Psoriatic Regulatory T cell DysfunctionR01AR051498 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · PI COOPER, KEVIN D · 2004 to 2014
$3.5M
SYNTHESIS OF PHTHALOCYANINES FOR TUMOR PHOTOTHERAPYP01CA048735 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI OLEINICK, NANCY L · 1990 to 2002
$3.3M
TRAINING IN INVESTIGATIVE AND MOLECULAR DERMATOLOGYT32AR007569 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · PI COOPER, KEVIN D · 1991 to 2019
$2.7M
PHOTOTHERAPY OF PROSTATE CANCER--PRO AND ANTI APOPTOSISR01CA083917 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI OLEINICK, NANCY L · 2000 to 2006
$2.3M
Cardiolipin in Photodynamic TherapyR01CA106491 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI OLEINICK, NANCY L · 2005 to 2008
$972k
NCI NIH HHS P01 CA048735NCI NIH HHS P01 CA48735NCI NIH HHS P30 CA043703NCI NIH HHS P30 CA43703NCI NIH HHS R01 CA083917NCI NIH HHS R01 CA106491NCI NIH HHS R01 CA83917NIAMS NIH HHS AR39750NIAMS NIH HHS P30 AR039750NIAMS NIH HHS R01 AR-051498NIAMS NIH HHS R01 AR051498NIAMS NIH HHS T32 AR-007569NIAMS NIH HHS T32 AR007569
6 · The paper itself

Abstract

Photodynamic therapy (PDT) is emerging as a promising non-invasive treatment for cancers. PDT involves either local or systemic administration of a photosensitizing drug, which preferentially localizes within the tumor, followed by illumination of the involved organ with light, usually from a laser source. Here, we provide a selective overview of our experience with PDT at Case Western Reserve University, specifically with the silicon phthalocyanine photosensitizer Pc 4. We first review our in vitro studies evaluating the mechanism of cell killing by Pc 4-PDT. Then we briefly describe our clinical experience in a Phase I trial of Pc 4-PDT and our preliminary translational studies evaluating the mechanisms behind tumor responses. Preclinical work identified (a) cardiolipin and the anti-apoptotic proteins Bcl-2 and Bcl-xL as targets of Pc 4-PDT, (b) the intrinsic pathway of apoptosis, with the key participation of caspase-3, as a central response of many human cancer cells to Pc 4-PDT, (c) signaling pathways that could modify apoptosis, and (d) a formulation by which Pc 4 could be applied topically to human skin and penetrate at least through the basal layer of the epidermis. Clinical-translational studies enabled us to develop an immunohistochemical assay for caspase-3 activation, using biopsies from patients treated with topical Pc 4 in a Phase I PDT trial for cutaneous T-cell lymphoma. Results suggest that this assay may be used as an early biomarker of clinical response.

Indexed as

AnimalsApoptosisClinical Trials, Phase I as TopicDrug Evaluation, PreclinicalHumansIndolesModels, BiologicalMolecular StructurePhotochemotherapyPhotosensitizing AgentsIndolesPhotosensitizing Agentsphthalocyanine Pc 4

Identifiers

PMID17397888
PMCPMC2128784
OpenAlexW2020232556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.